πŸ‡ΊπŸ‡Έ FDA

Intelligence Platform

Patents

Browse 1,015 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 11708406

Method of treating acute respiratory distress syndrome (ARDS) or acute lung injury (ALI) a

AVALO THERAPEUTICS, INC. Β· Granted Tue Jul 25 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 20 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11697676

Anti-human papillomavirus 16 E6 T cell receptors

The United States of America, as represented by the Secretary, Department of Health and Human Services Β· Granted Tue Jul 11 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 06 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11690918

Pyrrolobenzodiazepine-anti-CD22 antibody conjugates

ADC THERAPEUTICS SA Β· Granted Tue Jul 04 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 29 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11692032

Anti-LAG3 antibodies and uses thereof

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Jul 04 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 29 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11685784

Anti-immune-checkpoint nanobody and nucleic acid encoding sequence thereof, and uses of th

China Medical University Hospital Β· Granted Tue Jun 27 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 22 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11673967

Stabilized formulations containing anti-PCSK9 antibodies

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Jun 13 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 08 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11672785

Tetrahydro-1H-pyrido [3,4-b]indole anti-estrogenic drugs

Olema Pharmaceuticals, Inc. Β· Granted Tue Jun 13 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 08 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11672872

Anti-transferrin receptor antibody and uses thereof

Dyne Therapeutics, Inc. Β· Granted Tue Jun 13 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 08 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11667701

Anti-PfRH5 antibodies and antigen-binding fragments thereof

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Jun 06 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 01 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11655286

Anti-PcrV antibodies that bind PcrV, compositions comprising anti-PcrV antibodies, and met

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue May 23 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 18 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11655307

Anti-doublecortin-like kinase 1 antibodies and methods of use

The Board of Regents of the University of Oklahoma Β· Granted Tue May 23 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 18 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11654187

Horn fly protein as active antigen in anti-horn fly vaccine for protection of bovines agai

The United States of America, as represented by the Secretary of Agriculture Β· Granted Tue May 23 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 18 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11648318

Anti-transferrin receptor (TFR) antibody and uses thereof

Dyne Therapeutics, Inc. Β· Granted Tue May 16 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 11 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11648307

Anti-DC-HIL antibodies for cancer diagnosis, prognosis and therapy

The Board of Regents of the University of Texas System Β· Granted Tue May 16 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 11 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11649273

Anti-VEGF protein compositions and methods for producing the same

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue May 16 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 11 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11642390

Method of treatment with a fusion protein comprising apelin and an anti-APLNR antibody

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue May 09 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 04 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11633501

Anti-STEAP2 antibodies, antibody-drug conjugates, and bispecific antigen-binding molecules

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Apr 25 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 20 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11629195

Anti-IL2 receptor gamma antigen-binding proteins

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Apr 18 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 13 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11623010

Pharmaceutical carrier in the preparation of an anti-diabetic pharmaceutical composition a

BEIJING RONGXIANG INSTITUTE OF REGENERATIVE MEDICINE CO., LTD. Β· Granted Tue Apr 11 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 06 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11618784

Anti-CD47 combination therapy

TEVA PHARMACEUTICALS AUSTRALIA PTY LTD Β· Granted Tue Apr 04 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 30 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11608380

Anti-EGFRvIII antibodies and uses thereof

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Mar 21 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 16 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11603413

Anti-TMPRSS2 antibodies and antigen-binding fragments

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Mar 14 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 09 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11596688

Predicting outcome of treatment with an anti-Ξ±4Ξ²7 integrin antibody

Takeda Pharmaceutical Company Limited Β· Granted Tue Mar 07 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 02 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11596690

Stabilized formulations containing anti-IL-33 antibodies

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Mar 07 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 02 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted